TapImmune gets $3.1mm through private placement ahead of merger

15:40 EDT 12 Jun 2018 | Elsevier Business Intelligence

Cancer immunotherapies developer TapImmune Inc. sold 3.1mm common shares priced at $2.40 (an 18% discount) to its largest sha...

Original Article: TapImmune gets $3.1mm through private placement ahead of merger


More From BioPortfolio on "TapImmune gets $3.1mm through private placement ahead of merger"

Quick Search


Relevant Topics

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...

  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...